Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1999 1
2000 1
2001 5
2002 4
2003 6
2004 5
2005 2
2006 2
2007 2
2008 6
2009 5
2010 6
2011 5
2012 5
2013 5
2014 10
2015 8
2016 10
2017 6
2018 7
2019 5
2020 3
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 32471842

99 results
Results by year
Filters applied: . Clear all
Page 1
CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections.
Bernal CJ, Aka I, Carroll RJ, Coco JR, Lima JJ, Acra SA, Roden DM, Van Driest SL. Bernal CJ, et al. Pediatrics. 2019 Dec;144(6):e20190857. doi: 10.1542/peds.2019-0857. Epub 2019 Nov 7. Pediatrics. 2019. PMID: 31699831
CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
Egan LJ, Myhre GM, Mays DC, Dierkhising RA, Kammer PP, Murray JA. Egan LJ, et al. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1521-8. doi: 10.1046/j.1365-2036.2003.01645.x. Aliment Pharmacol Ther. 2003. PMID: 12823155 Free article.
Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.
Lang JE, Holbrook JT, Mougey EB, Wei CY, Wise RA, Teague WG, Lima JJ; American Lung Association-Airways Clinical Research Centers. Lang JE, et al. Ann Am Thorac Soc. 2015 Jun;12(6):878-85. doi: 10.1513/AnnalsATS.201408-391OC. Ann Am Thorac Soc. 2015. PMID: 25844821 Free PMC article. Clinical Trial.
99 results
Jump to page
Feedback